 |
2008
2007
2006
2005
May 09, 2008
Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
May 08, 2008
Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
May 06, 2008
Actress and Mom Lori Loughlin Raises Awareness About the Potential Dangers of Drowsy Driving During Allergy Season
April 30, 2008
Intervet/Schering-Plough Animal Health Outlines Strength of the Combination
April 26, 2008
Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
April 25, 2008
Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
April 24, 2008
Schering-Plough CEO Buys $2 Million in Common Shares
April 23, 2008
Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
Schering-Plough Reports Financial Results for First Quarter of 2008
April 17, 2008
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
April 16, 2008
Schering-Plough Announces Imperfect Contraceptive Use Impacts Women's Emotional Well-Being
April 15, 2008
Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
April 14, 2008
Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
April 11, 2008
Schering-Plough Announces Expanded Stock Retention Guidelines for Senior Management
April 02, 2008
Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
March 30, 2008
Merck/Schering-Plough Pharmaceuticals Comments on Results of the ENHANCE Study
March 27, 2008
Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C
March 20, 2008
New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly
March 18, 2008
The Makers of COPPERTONE Launch SPF 70+ the Highest SPF Continuous Spray Sunscreen Available
Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
March 11, 2008
FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
March 10, 2008
Schering-Plough to Webcast Presentation by CEO Fred Hassan at Lehman Brothers Eleventh Annual Global Healthcare Conference
February 29, 2008
Schering-Plough Promotes Ian McInnes to President of Global Supply Chain
Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
February 12, 2008
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
February 11, 2008
Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
February 08, 2008
Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
February 06, 2008
Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients
February 04, 2008
FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11
January 31, 2008
New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
January 25, 2008
Merck and Schering-Plough Respond To Issues Raised About ENHANCE Clinical Trial
January 22, 2008
FDA Approves Labeling Change for Non-Drowsy CLARITIN(R)
January 18, 2008
Schering-Plough CEO to Buy $2 Million in Common Shares
January 17, 2008
Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
January 14, 2008
Schering-Plough Reports Top-Line Results of the IDEAL Study
Merck/Schering-Plough Pharmaceuticals Provides Results of the ENHANCE Trial
January 03, 2008
Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
January 02, 2008
Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
|
|
About Us
CEO Fred Hassan's Remarks from the 3rd Annual Cardiovascular Summit: "Improving Cardiovascular Care: A Noble Mission."